ArticleJournal of neuro-oncology2025
Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeDrug resistance is a major challenge in the treatment of tumor diseases, especially in glioblastoma (GBM), where temozolomide (TMZ) plays a critical role. However, the development of resistance to TMZ occurs rapidly in more than half of the patients who initially respond to the drug. This highlights the need for novel approaches to overcome drug resistance and improve therapeutic outcomes in GBM treatment.
methodsIn our study, we combine TMZ treatment with wireless optoelectronics using advanced multilayered organic semiconductor (MOS) devices. These devices consist of a 200 nm thick stack of metal and p-n semiconducting organic nanocrystals. When illuminated in physiological solutions, these MOS devices charge up and convert light pulses into localized displacement currents, which are strong enough to electrically stimulate tumor cells at safe light intensities. Importantly, the freestanding MOS devices require no external wiring or bias and remain stable under physiological conditions. The semiconductor layers are created from common, non-toxic pigments using simple, scalable deposition methods.
resultsOur results demonstrate that this combination of TMZ and optoelectronic stimulation significantly enhances apoptosis in tumor cells, thereby improving the effectiveness of TMZ in treating glioblastoma.
conclusionhis research suggests that the integration of wireless optoelectronic stimulation with TMZ treatment offers a promising strategy to overcome drug resistance in GBM. The use of MOS devices enhances the therapeutic effect of TMZ and could lead to better treatment outcomes for patients with glioblastoma.
Indexed as
Identifiers
40694237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.